I-MAB SPONS.ADS/1 -0001
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial fo… Read more
I-MAB SPONS.ADS/1 -0001 (0VY) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, I-MAB SPONS.ADS/1 -0001 (0VY) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
I-MAB SPONS.ADS/1 -0001 - Net Assets Trend (None–None)
This chart illustrates how I-MAB SPONS.ADS/1 -0001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for I-MAB SPONS.ADS/1 -0001 (None–None)
The table below shows the annual net assets of I-MAB SPONS.ADS/1 -0001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to I-MAB SPONS.ADS/1 -0001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
I-MAB SPONS.ADS/1 -0001 Competitors by Market Cap
The table below lists competitors of I-MAB SPONS.ADS/1 -0001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Esab India Limited
NSE:ESABINDIA
|
$249.10 Million |
|
Bumi Armada Bhd
KLSE:5210
|
$249.13 Million |
|
CATARC Automotive Proving Ground Co.Ltd.
SHE:301215
|
$249.14 Million |
|
Shenzhen HeKeda Precision Cleaning Equipment Co Ltd
SHE:002816
|
$249.23 Million |
|
Guilin Sanjin Pharmaceutical Co Ltd
SHE:002275
|
$248.96 Million |
|
Ningbo Heli Mould Technology Co Ltd Class A
SHG:603917
|
$248.87 Million |
|
Objective Corporation Ltd
AU:OCL
|
$248.75 Million |
|
Shanghai Xujiahui Commercial Co Ltd
SHE:002561
|
$248.72 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in I-MAB SPONS.ADS/1 -0001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares I-MAB SPONS.ADS/1 -0001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently I-MAB SPONS.ADS/1 -0001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares I-MAB SPONS.ADS/1 -0001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| I-MAB SPONS.ADS/1 -0001 (0VY) | €- | N/A | N/A | $249.02 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |